diabetes - HealthQuill

Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat Alzheimer’s disease, diabetes and obesity, according to a company statement.

Eli Lilly to invest $1b in Irish facility to make Alzheimer’s, obesity drugs

Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat.

by HealthQuill
September 12, 2024
0 Comments

Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to 49 nations in Africa.

Drugs Health Pharma

Eli Lilly to license rheumatoid drug-making technology to Egypt’s EVA

Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to.

by HealthQuill
September 4, 2024
0 Comments

A new cardiovascular disease risk calculator may render 16 million US citizens ineligible for preventive therapy if the current guidelines for cholesterol and high blood pressure treatment remain the same, according to a Harvard Medical School study.

Drugs Health Pharma

New cardiovascular risk calculator may impose a burden on 16 million US citizens

HQ Team August 6, 2024: A new cardiovascular disease risk calculator may render 16 million US citizens ineligible for preventive therapy if the.

by HealthQuill
August 6, 2024
0 Comments

Researchers have added two additional risk factors — untreated vision loss and high LDL cholesterol — to 12 other steps to identify dementia, projected to affect 153 million people by 2050.

Drugs Health Pharma

Untreated vision loss, high LDL cholesterol risk factors for dementia

Researchers have added two additional risk factors — untreated vision loss and high LDL cholesterol — to 12 other steps to identify dementia,.

by HealthQuill
August 5, 2024
0 Comments

French drugmaker Sanofi SA will build a 1.3 billion euro ($1.4 billion) insulin manufacturing facility in Germany’s Frankfurt to secure the long-term supply of the medicine.

Drugs Health Pharma

Sanofi to invest $1.4 billion to build new insulin plant in Frankfurt

French drugmaker Sanofi SA will build a 1.3 billion euro ($1.4 billion) insulin manufacturing facility in Germany’s Frankfurt to secure the long-term supply.

by HealthQuill
August 1, 2024
0 Comments

The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic adults with obesity, according to a statement from the EU regulator.

Drugs Health Pharma

Wegovy gets EU regulator backing on lowering heart risks in obese people

The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic.